YR0139
Human Trop-2 Monoclonal Antibody, Endotoxin 0.05 EU/mg
Size
£1,303.00
- SKU:
- YR0139
- Additional Names:
- EGP-1|EGP1|GA733-1|GA7331|GP50|M1S1|TACSTD2|TROP2
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human Trop-2
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P09758
- Synonyms:
- 40kD glycoprotein, identified by monoclonal antibody GA733;cell surface glycoprotein Trop-2;cell surface glycoprotein TROP2;EGP-1;EGP1;epithelial glycoprotein-1;GA733-1;GA7331;gastrointestinal tumor-associated antigen GA7331;GP50;M1S1;Membrane component chromosome 1 surface marker 1;membrane component, chromosome 1, surface marker 1;pancreatic carcinoma marker protein GA733-1;pancreatic carcinoma marker protein GA7331;TROP2;trophoblast cell surface antigen 2;truncated TACSTD2;tumor-associated calcium signal transducer 2
- Extra Details:
- Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
- Shipping Conditions:
- Blue Ice